AC 162352

Drug Profile

AC 162352

Alternative Names: peptide YY3-36

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Curis
  • Developer Amylin Pharmaceuticals
  • Class Obesity therapies; Peptide hormones; Peptides
  • Mechanism of Action Peptide hormone stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Obesity

Most Recent Events

  • 24 Feb 2010 Discontinued - Phase-I for Obesity in USA (SC)
  • 10 Jun 2008 Pharmacodynamics data from a preclinical trial in obesity presented at the The 68th Scientific Sessions of the American Diabetes Association (ADA-2008)
  • 06 Sep 2006 This compound is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top